Charleston Life Sciences

Charleston, SC – January 13, 2009 – FirstString Research, a biotechnology company focused on the development and commercialization of therapeutics for scar prevention and tissue regeneration, is today announcing that Carl Ehmann, MD joins the Scientific Advisory Board. Dr. Ehmann was Executive Vice President for Johnson & Johnson Consumer Products, and the former Global Head of R&D at Reckitt & Coleman.

“Dr. Ehmann’s experience as a research and development leader of several large multi-national companies and his familiarity with advising both early stage and established companies will be an invaluable asset to FirstString,” said Dr. Gautam Ghatnekar, President and CEO of FirstString. “Due to our promising early clinical studies, we are now in a position to attract pioneers in the field of wound care.”

FirstString is currently conducting its Phase I clinical trial in Switzerland.

“This is an exciting time to be joining FirstString’s Scientific Advisory Board,” stated Dr. Ehmann. “I am delighted to be part of the ongoing development of this exciting new wound care product.”

About FirstString
FirstString is a biotechnology company focused on the development and commercialization of therapeutics for scar prevention and tissue regeneration. There is a significant unmet medical need for the prevention of scarring resulting from surgeries and injuries. FirstString is endeavoring to meet that need by developing a class of compounds, which form the platform of this exciting technology.

FirstString's proprietary therapies modulate intercellular communication to significantly reduce the development of scar tissue and, at the same time, improve the body's ability to produce healthy, functional cells. The lead compound's target is well expressed and has shown efficacy in many tissue types including the skin, spinal cord and internal organs.

FirstString's first commercial product will be a topical gel for the prevention of scarring. Based on the consistent and positive early results, FirstString has already received regulatory approval in Europe to enter clinical phase testing. For further information, please visit www.firststringresearch.com. 

###
For Media Inquiries:
Dr. Gautam S. Ghatnekar
President and CEO - FirstString Research, Inc.
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
843-860-8785